In the treatment field of cardiac hypertrophy, current therapeutic approaches often focus on managing risk factors (e.g., hypertension) or blocking the action of neurohormonal factors However, drugs that modulate the function or expression of p130Cas or interfere with its downstream signaling pathways could offer novel treatments for cardiac myocyte hypertrophy [5]. This evidence concerns the gene BCAR1 and cardiac hypertrophy.